Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

LifeMD (LFMDP) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for LifeMD (LFMDP) over the last 14 years, with Q3 2025 value amounting to 3.27%.

  • LifeMD's EBITDA Margin rose 42300.0% to 3.27% in Q3 2025 from the same period last year, while for Sep 2025 it was 2.15%, marking a year-over-year increase of 75200.0%. This contributed to the annual value of 8.75% for FY2024, which is 7500.0% up from last year.
  • As of Q3 2025, LifeMD's EBITDA Margin stood at 3.27%, which was up 42300.0% from 0.72% recorded in Q2 2025.
  • LifeMD's EBITDA Margin's 5-year high stood at 1.52% during Q1 2025, with a 5-year trough of 72.27% in Q2 2021.
  • Its 5-year average for EBITDA Margin is 24.56%, with a median of 13.62% in 2023.
  • Within the past 5 years, the most significant YoY rise in LifeMD's EBITDA Margin was 2008900bps (2021), while the steepest drop was -368700bps (2021).
  • Quarter analysis of 5 years shows LifeMD's EBITDA Margin stood at 49.84% in 2021, then grew by 26bps to 36.88% in 2022, then skyrocketed by 87bps to 4.84% in 2023, then plummeted by -33bps to 6.46% in 2024, then skyrocketed by 49bps to 3.27% in 2025.
  • Its EBITDA Margin was 3.27% in Q3 2025, compared to 0.72% in Q2 2025 and 1.52% in Q1 2025.